

INDEX

A

- Active immunotherapy97
- Acute myeloid leukemia (AML) 115, 118, 120–125, 141, 142
- Advanced therapy medicinal products (ATMP)
- Alloreactivity 141–144
- Antibodies 11–24, 41, 47, 49, 68, 69, 75, 78, 88, 89, 91, 93, 94, 116, 129, 133–138, 143, 144, 149, 150, 154, 155
- Antigen presenting cells (APCs) 38, 41, 44–46, 49, 50, 99
- Antitumor vaccines
 - mRNA-loaded dendritic cells
 - T cells as antigen carriers 82, 84
- Autoantibodies 11

B

- Bioluminescence 95, 105, 107–110
- Buffy coat 128–130

C

- Cancer immunotherapy 2, 4–8, 27–34, 75–85
- Cancer-related inflammation 87
- CAR. *See* Chimeric antigen receptors (CARs)
- Cell therapy medicinal products (CTMP) 1, 2, 4, 5, 128, 130
- Chemokines 38, 87–96
- Chimeric antigen receptors (CARs) 1, 75–85
- CHMP. *See* Committee for Human Medicinal Products (CHMP)
- Clinical grade 27–34, 103
- Coelenterazine 107, 109–111
- Colloidal coomassie blue staining 15, 20, 21
- Committee for advanced therapy (CAT) 2, 3
- Committee for human medicinal products (CHMP) 2, 3
- Cross-presentation 99
- Cytokines 38, 48, 50, 57, 64, 76, 87, 115, 116

D

- Dendritic cells 2, 27, 49, 50, 54, 60–64, 128, 141

E

- Efficacy profile of cancer immunotherapies 5
- EMA. *See* European Medicine Agency (EMA)
- Engrafting immunocompromised mice with human cells
 - cancer cell lines 159
 - primary tumors 156, 157
 - T cells 130, 131
- European Medicine Agency (EMA) 2–6
- European regulation for advanced therapy medicinal products 1

F

- Firefly luciferase (intracellular) 63, 79
- Flow cytometry 72, 88, 105, 121, 134, 135

G

- Gaussia luciferase (secreted) 105–111
- Gene delivery
 - DNA transfection 80
 - mRNA electroporation 28, 29, 33
 - viral-mediated transduction 106
- Generation of antigen-specific T cells from human pluripotent stem cells 68, 73
- Generation of human monocyte-derived mature DC 28–30
- Gene silencing (by RNA interference) 113–115
- Gene therapy medicinal products (GTMP) 1–6
- Genotoxicity 6
- GMP. *See* Good manufacturing practice (GMP)
- Good manufacturing practice (GMP) 6–8, 33, 103
- Graft-versus-host disease 127–132

H

- Hematopoietic stem cell transplantation (HSCT) 127
- Hematopoietic stem/progenitor cells 68–69, 71–72
- Histology 88, 89, 92, 149, 154

I

- Immunocompromised mice 127–132
- Immunohistochemistry 41–42, 156, 158
- Immunomodulating antibodies 133

- Immunoproteomics 11, 12
 Induced pluripotent stem cells (iPSCs) 71–72
 Insertional mutagenesis 4, 6, 28
 Institutional Animal Care and Use Committee (IACUC) 128
 In vitro tumor model (microtumors) 148, 150–159
 In vivo imaging 79, 85, 93–95, 105–107, 110
 Isoelectric focusing (IEF) 16–18
 Isolation of human peripheral blood mononuclear cells (PBMCs) 40–44, 46, 48–50, 56, 60, 64, 72, 81, 159
- K**
- KIR genotyping 142–144
 KIR phenotyping 142–144
- L**
- Liver X receptors (LXR) 53–56, 58–60, 62–63
 Luciferase-based assays 63
 Luciferin 79, 85, 90, 93, 95
 Luminometer 56, 60, 107, 110
- M**
- Magnetic cell separation 70
 Melanoma 12, 54, 88, 156, 157, 159
 Metastasis 87, 88, 93
 Microenvironment 38
 Minor histocompatibility antigens 149, 159
 Mixed leukocyte reaction 88
 Molecular cloning
 bacteria transformation 107, 117
 digestion 116
 ligation 107, 110, 116, 117, 124
 Multiplicity of infection (MOI) 71, 73
- N**
- NK cells 27, 127, 141–144
- O**
- Oxysterols 53
- P**
- Paramagnetic beads conjugated with anti-CD3/CD28 antibodies 68, 143
 Paramagnetic cell separation 107, 108
 Peptide synthesis 40, 43
 Pharmacovigilance Risk Assessment Committee (PRAC) 3
 Phytohaemagglutinin (PHA) 44, 69, 72, 144
 PRAC. *See* Pharmacovigilance Risk Assessment Committee (PRAC)
 Production of (retro-/lenti-) viral supernatant 79–81
- Protein precipitation 13, 16–17
 Protein quantitation 13, 17
- Q**
- Quality control (QC) 7, 33
 Quantitative PCR 58, 62–64
- R**
- Reprogramming human antigen-specific T cells into pluripotent stem cells 68
 Restriction enzymes 77, 106, 107
- S**
- Safety profile of cancer immunotherapies 147–160
 SDS-PAGE. *See* SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 14, 18–19
 Selection markers for the isolation of transduced cells 101–103
 Sera collection from human blood samples 13, 16
 Short-hairpin RNAs (shRNAs) 114, 115, 120
- T**
- TAA. *See* Tumor-associated antigens (TAAs)
 T cell clone 68, 70, 72, 73
 T-cell co-culture assay 78, 82–84
 T-cell cytokine release assay 79
 T-cell cytotoxicity assay 78, 82
 T-cell immunotherapy 68
 T-cell proliferation assay (with CFSE) 45, 46
 T cell receptor (TCR) 38, 67, 72, 73, 75, 76
 T cells 27, 38–40, 42–46, 48–50, 67–73, 75–77, 79–85, 88, 92, 141
 T-cell stimulation protocols
 antigen-specific 67, 68, 70, 72, 73
 polyclonal 75
 TEP. *See* Tissue engineering (TEP)
 Tetramers 68, 70, 72
 Three-dimensional (3D) tumor model 147–160
 Th subsets 38, 39, 50
 Tissue engineering (TEP) 1, 2, 4
 Total RNA extraction 57, 61–62
 Transduction
 primary tumor cells 120–121
 T cells 101–103
 tumor cell lines 106–107, 118–120
 Tumor-associated antigens (TAAs) 11, 12
 Tumor-conditioned media 63
 Tumor disaggregation 89–92
 Tumor-infiltrating leukocytes
 dendritic cells
 T cells 91
 Tumor-reactive T cells

genetically engineered..... 88, 98, 99
 natural75
 natural..... 11–24, 27
 Two-dimensional (2D) gel electrophoresis..... 11, 15

V

Viral vectors
 lentiviral.....106–108, 115–118, 120–121
 retroviral 72, 76, 77, 79–81, 98, 100, 103, 115

W

Western blot analysis24
 Wilms' tumor protein 1 (WT1)28

X

Xenogeneic graft-versus-host disease
 model..... 127, 128, 130, 131
 Xenograft mouse models